FDA ad­vi­sors most­ly agree that Aca­dia’s Nu­plazid is­n't ef­fec­tive at treat­ing Alzheimer’s-re­lat­ed psy­chosis

A pan­el of the FDA’s out­side ex­perts vot­ed 9-3 that Aca­dia Phar­ma­ceu­ti­cals’ drug doesn’t ap­pear to be ef­fec­tive at treat­ing pa­tients with Alzheimer’s-re­lat­ed psy­chosis. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER